Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - Triplets

Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - QuadrupletsПодробнее

Debate: What is the best induction therapy in transplant-eligible myeloma patients? - CombinationПодробнее

Debate: What is the best induction therapy in transplant-eligible myeloma patients? - SequentialПодробнее

Debate: Frontline Regimen for Newly Diagnosed Transplant Ineligible Myeloma - Three DrugsПодробнее

Debate: Frontline Regimen for Newly Diagnosed Transplant Ineligible Myeloma - Two DrugsПодробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

Treatment for Transplant Eligible Myeloma Patients: Doublets-Triplets?Подробнее

Debate: Myeloma maintenance post-transplant - IndefiniteПодробнее

Best Treatment Options for Transplant Ineligible Myeloma Patients: Doublets-Triplets?Подробнее

Induction & consolidation therapy in newly diagnosed multiple myelomaПодробнее

Induction therapy in newly diagnosed multiple myelomaПодробнее

Triplet Therapy, Transplantation, and Maintenance in Myeloma | NEJMПодробнее

Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidationПодробнее

The changing landscape of induction therapy for newly diagnosed multiple myelomaПодробнее

Debate: Is allotransplant relevant today in myeloma? - NoПодробнее

An update on the RADAR trial: RCyBorD as induction therapy in newly diagnosed multiple myelomaПодробнее

Debate: Induction therapy for multiple myeloma - Based on an IMiD and a proteasome inhibitorПодробнее

Addition of Isatuximab to RVd As Induction Therapy for Newly-Diagnosed, Transplant-Eligible MM PtsПодробнее

Dr. Vij on the Optimal Induction Therapy in Multiple MyelomaПодробнее